FASN and cancer: TCGA pan-cancer analyses showed a robust negative correlation between FASN expression and cytolytic activity, HLA-I, and HLA-II immune signatures (PCCs = −0.22, −0.23, −0.26, FDR-adjusted p-values < 10−100).